# MedRhythms

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medrhythms

- Industry: Medical Devices & Equipment
- Headquarters: Portland, US
- Website: www.medrhythms.com/
- Total disclosed funding: $32M
- Latest round: Series B (Nov 16, 2021)
- Investors on record: 5

## About

MedRhythms Inc. is a US-based company pioneering digital neurotherapeutics that harness the power of music and technology to improve brain health and mobility for individuals with neurological disabilities.Founded in 2013, MedRhythms Inc. focuses on developing digital therapeutics that enhance mobility in patients suffering from neurological conditions. The company is headquartered in Portland, US. Brian Harris and Owen McCarthy founded the company, with Brian Harris currently serving as CEO. MedRhythms has completed a total of 9 deals, with its most recent funding round, a Series B, occurring on April 29, 2025, raising USD 19.781 mn, bringing the total amount raised to USD 19.781 mn and valuing the company at USD 74.337 mn.MedRhythms specializes in next-generation neurotherapeutics that utilize music and technology to enhance brain health, particularly for individuals with walking disabilities due to neurologic injuries or diseases. The company's core offering is Rhythmic Auditory Stimulation (RAS), a patented technology combining sensors, software, and curated music to target neural circuitry and improve mobility. Their digital therapeutics platform addresses neurological conditions like stroke, multiple sclerosis, and Parkinson’s disease, serving clinicians, healthcare providers, and directly benefiting patients with gait disorders, primarily in the United States.MedRhythms generates revenue through partnerships and B2B sales with healthcare providers and institutions, centered on its flagship product, InTandem™, which is available by prescription. Revenue is derived from digital therapeutics subscriptions enabling healthcare providers to integrate MedRhythms’ technology into their practices, facilitating music-based interventions for patients with mobility challenges. Specific pricing plans are not disclosed, focusing on accessibility within the healthcare ecosystem.MedRhythms plans to expand its product offerings and geographical reach. The company is in the process of designing new products to enhance its digital therapeutics platform. Plans for entering new markets include targeting additional regions with significant populations affected by neurological conditions. The recent Series B funding of USD 19.781 mn will be utilized to support these initiatives, which include expanding their presence in the healthcare sector and developing new therapeutic products. Additionally, in April 2025, MedRhythms Inc. secured venture funding from CEI Ventures Management, alongside participation from returning investor Community Development Venture Capital Alliance.

## Funding rounds

- Series B, Nov 16, 2021, $2M — Global Brain, Bose Ventures
- Series B, Jul 28, 2021, $25M — Advantage Capital, Werth Family Investment Associates, Morningside
- Series A, Jun 29, 2018, $5.3M — Werth Family Investment Associates

## Investors

- Werth Family Investment Associates (https://capitalatlas.ai/funds/werth-family-investment-associates) — Series A, Series B
- Advantage Capital — Series B
- Morningside (https://capitalatlas.ai/funds/morningside) — Series B
- Global Brain (https://capitalatlas.ai/funds/global-brain) — Series B
- Bose Ventures (https://capitalatlas.ai/funds/bose-ventures) — Series B